Objective Epigenetic mechanisms allow cells to adjust gene expression in response to environmental cues. Increased understanding of this area has led to excitement about the potential of applying epigenetic regulation to drug discovery. EPIMAC aims to pursue the potential of epigenetics as a novel and innovative therapeutic modality for immuno-inflammatory diseases, in particular Inflammatory Bowel Disease (IBD). IBD is a severe and disabling chronic inflammation of the gastrointestinal tract affecting millions of people worldwide. Current treatment strategies are not successful because the precise etiology unclear. It is increasingly clear that deregulated epigenetic processes are associated with the aberrant inflammatory response seen in IBD. Recent reports suggest that inhibitors of epigenetic modifications developed by GlaxoSmithKline (GSK), such as histone deacetylase (HDAC) inhibitors, bear potential in treating inflammatory states (Nicodeme et al, Nature 2010; Kruidenier et al, Nature 2012). The EPIMAC consortium has the ambition to educate a group of next-generation scientists that master genetics, epigenetics, target discovery, pharmacology, preclinical validation and regulatory issues, and at the same time have a good understanding of clinical implementations of the drug pipeline of our pharmaceutical partner GSK. GSK is one of the world's leading research-based pharmaceutical and healthcare companies that aims to team up with academic partners in EPIMAC through its dedicated discovery performance unit named EpiNova in conjunction with 2 immuno-pharmacology units. An SME specializing in epigenetic compound targeting to inflammatory cells, Chroma Therapeutics, will contribute technology to EPIMAC. EPIMAC will educate and train these scientists by providing them with a versatile and multidisciplinary doctoral program, allowing them to become excellent scientists skilled to overcome the current challenges in IBD. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth sciencesinflammatory diseasesmedical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasemedical and health sciencesbasic medicineimmunologynatural sciencesbiological sciencesgeneticsepigenetics Keywords Gastroenterology Inflammatory Bowel Diseases Drug Development Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.1. - Fostering new skills by means of excellent initial training of researchers Topic(s) MSCA-ITN-2014-EID - Marie Skłodowska-Curie Innovative Training Networks (ITN-EID) Call for proposal H2020-MSCA-ITN-2014 See other projects for this call Funding Scheme MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN) Coordinator AMC MEDICAL RESEARCH BV Net EU contribution € 1 021 497,12 Address MEIBERGDREEF 9 1105AZ Amsterdam Zuidoost Netherlands See on map Region West-Nederland Noord-Holland Groot-Amsterdam Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 1 021 497,12 Participants (2) Sort alphabetically Sort by Net EU contribution Expand all Collapse all GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. United Kingdom Net EU contribution € 273 287,88 Address Great West Road 980 TW89GS Brentford See on map Region London Outer London — West and North West Hounslow and Richmond upon Thames Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 273 287,88 ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM Netherlands Net EU contribution € 0,00 Address MEIBERGDREEF 15 1105AZ Amsterdam See on map Region West-Nederland Noord-Holland Groot-Amsterdam Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data Partners (2) Sort alphabetically Sort by Net EU contribution Expand all Collapse all Partner Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement. UNIVERSITAIR MEDISCH CENTRUM UTRECHT Netherlands Net EU contribution € 0,00 Address HEIDELBERGLAAN 100 3584 CX Utrecht See on map Region West-Nederland Utrecht Utrecht Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data Partner Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement. Eureka Net EU contribution € 0,00 Address See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost No data